Brexit: U.K. will become 'Third Country' according to EU Statement

Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The EU Commission and EMA made a clear statement that after 30 March 2019, the Unit Kingdom will become a 'third country'.
In a common Notice to marketing authorisation holders of centrally authorised medicinal products for human and veterinary use, the Commission and the Agency get the point strait that "all Union primary and secondary law ceases to apply to the United Kingdom from 30 March 2019, 00:00h (CET). That means that the U.K. will "become a 'third country'".
What does this mean for marketing authorisation holders? In the document, important aspects are listed which will need to be considered:
- EU law requires that marketing authorisation holders are established in the EU (or EEA). That means a pharmaceutical company will need a registered and licenced office or facility with licence in the EU/EEA.
- Some activities like, for example, batch release and pharmacovigilance activities must be performed in the EU (or EEA). So QP and QPPV must be located in the EU/EEA.
- Possible changes to the terms of the marketing authorisation "in order to ensure its continuous validity and exploitation" should be considered.
As a further step a series of Questions and Answers will be provided and the EMA's website will constantly be updated.
Related GMP News
06.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years